APO B/APO A1 RATIO AND ITS CORRELATION WITH CARDIOMETABOLIC RISK FACTORS AND OXIDATIVE STRESS IN SUBJECTS WITH METABOLIC SYNDROME

Deepthy C Sahadevan, Dr Archna Singh, Dr Busi Karunanand, Himani Thakkar, Ajay Kumar Gautam

Abstract


Objective: This study was designed to assess the apolipoprotein B (Apo-B), apolipoprotein A (Apo A) and Apo B/Apo A-I ratio in subjects with and
without metabolic syndrome and to evaluate the correlation of Apo B/Apo A-I ratio with oxidative stress marker and cardiovascular disease risk.
Methods: A total of 308 subjects including one hundred and fty- ve cases and one hundred and fty- three controls were recruited for this study.
All the subjects were classied according to the NCEP ATP III (National cholesterol education program – Adult treatment panel III) criteria for
MetS. Anthropometric and clinical characteristics were recorded using clinical Proforma. Blood samples were collected for doing plasma glucose,
Lipid prole analysis [Total Cholesterol (TC), Triglyceride (TG), high-density lipoprotein (HDL)], ApoA1, Apo B and oxidative stress marker -
Malondialdehyde (MDA). Serum low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and Apo B/Apo A-I ratio were calculated.
Comparison of data between the two groups was done by t test. Correlation coefcient of Apo B/ Apo A1 ratio with cadiometabolic risk factors were
calculated.
Result: We found that cardiometabolic risk factors like abdominal obesity, systolic and diastolic blood pressure, fasting plasma glucose, TG,
atherogenic lipoproteins LDL, Apo B, Apo B/Apo A-I ratio and MDA were signicantly high in subjects with MetS whereas anti-atherogenic
factor Apo A1 was signicantly low. We also observed that Apo B/AI ratio was positively related to cardiometabolic risk factors and with oxidative
stress marker.
Conclusion: Apo B/AI ratio was related to metabolic syndrome and was found to be a reliable indicator of cardiovascular risk in MetS.


Full Text:

PDF

References


Sinha S, Misra P, Kant S, Krishnan A, Nongkynrih B, Vikram NK. Prevalence of metabolic syndrome and its selected determinants among urban adult women in South Delhi, India. Postgraduate medical journal. 2013 Feb 1;89(1048):68-72.

Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life sciences. 2009 May 22;84(21-22):705-12.

Alfadda AA, Al-Daghri NM, Malabu UH. Apolipoprotein B/apolipoprotein AI ratio in relation to various definitions of metabolic syndrome among Saudi patients with type 2 diabetes mellitus. Saudi medical journal. 2008;29(6):821-5.

Jing F, Mao Y, Guo J, Zhang Z, Li Y, Ye Z, Ding Y, Wang J, Jin M, Chen K. The value of Apolipoprotein B/Apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study. Lipids in health and disease. 2014 Dec; 13(1):81.

Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program–Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes care. 2007 Jan 1;30(1):8-13.

Davidson MH. Apolipoprotein measurements: is more widespread use clinically indicated?. Clinical Cardiology: An International Indexed and Peer‐Reviewed Journal for Advances in the Treatment of Cardiovascular Disease. 2009 Sep;32(9):482-6.

Huang R, Silva RG, Jerome WG, Kontush A, Chapman MJ, Curtiss LK, Hodges TJ, Davidson WS. Apolipoprotein AI structural organization in high-density lipoproteins isolated from human plasma. Nature structural & molecular biology. 2011 Apr;18(4):416.

Yan S, Li J, Li S, Zhang B, Du S, Gordon‐Larsen P, Adair L, Popkin B. The expanding burden of cardiometabolic risk in China: the China Health and Nutrition Survey. Obesity Reviews. 2012 Sep;13(9):810-21.

Krychtiuk KA, Kastl SP, Pfaffenberger S, Lenz M, Hofbauer SL, Wonnerth A, Koller L, Katsaros KM, Pongratz T, Goliasch G, Niessner A. Association of small dense LDL serum levels and circulating monocyte subsets in stable coronary artery disease. PloS one. 2015 Apr 7;10(4):e0123367.

Rosú SA, Rimoldi OJ, Prieto ED, Curto LM, Delfino JM, Ramella NA, Tricerri MA. Amyloidogenic propensity of a natural variant of human apolipoprotein AI: stability and interaction with ligands. PLoS One. 2015 May 7;10(5):e0124946.

Walldius G, Jungner I. The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy–a review of the evidence. Journal of internal medicine. 2006 May;259(5):493-519.

Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes research and clinical practice. 2014 Aug 1;105(2):141-50.

Gyárfás I, Keltai M, Salim Y. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries in a case-control study based on the INTERHEART study. Orvosi hetilap. 2006 Apr; 147(15):675-86.

Zhong L, Li Q, Jiang Y, Cheng D, Liu Z, Wang B, Luo R, Cheng Q, Qing H. The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population. Inflammation. 2010 Dec 1;33(6):353-8.


Refbacks

  • There are currently no refbacks.